🇺🇸 FDA

Intelligence · Patent portfolio

Regeneron Ireland Designated Patents

Full USPTO pharma patent portfolio for Regeneron Ireland Designated — grant dates, expiration, and drug cross-links.

Patents
8,292
Expiring ≤24m
426

Quick answer

Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months — use filters for patent-cliff planning.

Page 84 of 173

  1. US 9512204

    Humanized pertussis antibodies and uses thereof

    Expires Mon Dec 01 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 9512191

    Methods and compositions for treating neurodegenerative disorders and alzheimer's disease and improving normal memory

    Expires Mon Dec 01 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 9512180

    Compstatin analogs

    Expires Mon Dec 01 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 9505781

    Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof

    Expires Mon Nov 24 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 9506926

    Molecular predictors of therapeutic response to specific anti-cancer agents

    Expires Mon Nov 24 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 9505766

    Kinase inhibitors

    Expires Mon Nov 24 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 9504745

    Compositions and methods for cancer treatment using targeted carbon nanotubes

    Expires Mon Nov 24 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 9504736

    Administration of serine protease inhibitors to the stomach

    Expires Mon Nov 24 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 9506040

    Prevascularized constructs for implantation to provide blood perfusion

    Expires Mon Nov 24 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 9505809

    Proteins with repetitive bacterial-IG-like (BIG) domains present in Leptospira species

    Expires Mon Nov 24 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 9505782

    Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof

    Expires Mon Nov 24 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 9505778

    Monomers, polymers and articles containing the same from sugar derived compounds

    Expires Mon Nov 24 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 9505768

    Compositions and methods for modulating TLR4

    Expires Mon Nov 24 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 9504754

    Curcuminoid complexes with enhanced stability, solubility and/or bioavailability

    Expires Mon Nov 24 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 9504730

    Method of achieving a thymosin beta 4 concentration in a human patient

    Expires Mon Nov 24 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 9504742

    Compositions for stimulation of mammalian innate immune resistance to pathogens

    Expires Mon Nov 24 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 9504688

    Methods and compositions for treating bacterial infection

    Expires Mon Nov 24 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 9504701

    Methods for treating viral infections using hydrogen sulfide donors

    Expires Mon Nov 24 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 9504658

    Stabilized HME composition with small drug particles

    Expires Mon Nov 24 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 9498533

    Drug delivery compositions and methods

    Expires Mon Nov 17 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 9498571

    Nitric oxide delivery devices

    Expires Mon Nov 17 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 9502711

    Fabrication of biscrolled fiber using carbon nanotube sheet

    Expires Mon Nov 17 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 9499800

    Methods of making and using chemically self assembled-nanorings

    Expires Mon Nov 17 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 9499606

    Compositions of, and methods for, alpha-1 anti trypsin Fc fusion molecules

    Expires Mon Nov 17 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 9499595

    Development of influenza A antivirals

    Expires Mon Nov 17 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 9499588

    Flaviviruses expressing the prM, E, and NS1 proteins of other flaviviruses and uses thereof

    Expires Mon Nov 17 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 9498544

    Genetically modified human umbilical cord perivascular cells for prophylaxis against or treatment of biological or chemical agents

    Expires Mon Nov 17 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 9498566

    Selective cytopheresis devices and related methods thereof

    Expires Mon Nov 17 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 9498537

    Method of enhancing efficacy of blood transfusions

    Expires Mon Nov 17 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 9499608

    Bispecific monoclonal antibody therapeutics against West Nile virus with improved CNS penetration

    Expires Mon Nov 17 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 9498471

    Use of CDK9 inhibitors to reduce cartilage degradation

    Expires Mon Nov 17 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 9493757

    Modified factor VII or factor VIIa polypeptides

    Expires Mon Nov 10 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 9493493

    Nucleotide analogs

    Expires Mon Nov 10 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 9492538

    Isolation and use of solid tumor stem cells

    Expires Mon Nov 10 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 9492477

    Compositions comprising citrate and applications thereof

    Expires Mon Nov 10 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 9493833

    Methods for preventing induced synthesis of proteasomes in human cells

    Expires Mon Nov 10 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 9493760

    Fungal-specific metalloproteases and uses thereof

    Expires Mon Nov 10 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 9493527

    Compositions and methods for the delivery of nitric oxide

    Expires Mon Nov 10 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 9493526

    Compositions and methods for the delivery of oxygen

    Expires Mon Nov 10 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 9493467

    PI3 kinase antagonists

    Expires Mon Nov 10 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 9492569

    Antibodies that bind integrin alpha-V beta-8

    Expires Mon Nov 10 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 9492523

    Broadly protective Shigella vaccine based on type III secretion apparatus proteins

    Expires Mon Nov 10 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 9492520

    Fusion molecule based on novel TAA variant

    Expires Mon Nov 10 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 9492484

    Cardiosphere derived cell population and methods of use

    Expires Mon Nov 10 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 9492415

    Methods of treating Parkinson's disease using viral vectors

    Expires Mon Nov 10 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 9487579

    Methods and compositions for modulation of blood-neural barrier

    Expires Mon Nov 03 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 9486401

    Use of cellular extracts for skin rejuvenation

    Expires Mon Nov 03 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 9487575

    Compositions and methods for treatment of gynecologic cancers

    Expires Mon Nov 03 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Regeneron Ireland Designated have?

8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Regeneron Ireland Designated patents expire?

426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources · Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.